RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of KURA
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Kura Oncology stock price up 3.67% on Wednesday
(Updated on Mar 27, 2024)

Sell candidate since Mar 25, 2024 Gain 0.86% PDF

The Kura Oncology stock price gained 3.67% on the last trading day (Wednesday, 27th Mar 2024), rising from $20.42 to $21.17. During the last trading day the stock fluctuated 4.74% from a day low at $20.27 to a day high of $21.23. The price has been going up and down for this period, and there has been a -7.27% loss for the last 2 weeks. Volume fell on the last day by -166 thousand shares and in total, 612 thousand shares were bought and sold for approximately $12.96 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 49.77% during the next 3 months and, with a 90% probability hold a price between $29.40 and $37.93 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

KURA Signals & Forecast

Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Kura Oncology stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $21.28 and $21.18. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, March 08, 2024, and so far it has fallen -10.03%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Kura Oncology stock

Kura Oncology finds support from accumulated volume at $20.85 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.96 between high and low, or 4.74%. For the last week, the stock has had daily average volatility of 5.11%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (KURA) For The Upcoming Trading Day Of Thursday 28th

For the upcoming trading day on Thursday, 28th we expect Kura Oncology to open at $20.89, and during the day (based on 14 day Average True Range), to move between $20.02 and $22.32, which gives a possible trading interval of +/-$1.15 (+/-5.42%) up or down from last closing price. If Kura Oncology takes out the full calculated possible swing range there will be an estimated 10.83% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $21.38 (0.99%) than the support at $20.85 (1.51%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Kura Oncology stock A Buy?

The Kura Oncology stock holds several negative signals and despite the positive trend, we believe Kura Oncology will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -3.917 Sell Candidate Unchanged

Predicted Opening Price for Kura Oncology of Thursday, March 28, 2024

Fair opening price March 28, 2024 Current price
$20.89 ( 1.34%) $21.17

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for KURA

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 21.85 3.20 %
R2 21.48 1.46 %
R1 21.25 0.394 %
Current price: 21.17
Support S1 20.52 -3.07 %
S2 20.29 -4.14 %
S3 19.93 -5.87 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 22.70 7.23 %
R2 22.34 5.53 %
R1 21.38 0.99 %
Current price 21.17
Support S1 20.85 -1.51%
S2 19.61 -7.37%
S3 18.73 -11.53%

FAQ

What is the symbol for Kura Oncology Stock and on which exchange is it traded?
The symbol for Kura Oncology is KURA and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Kura Oncology Stock?
The Kura Oncology stock holds several negative signals and despite the positive trend, we believe Kura Oncology will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Kura Oncology Stock?
Kura Oncology Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Kura Oncology Stock.

What's the current price of Kura Oncology Stock?
As of the end of day on the 2024-03-27, the price of an Kura Oncology (KURA) share was $21.17.

What is the 52-week high and low for Kura Oncology Stock?
The 52-week high for Kura Oncology Stock is $24.16 and the 52-week low is $7.41.

What is the market capitalization of Kura Oncology Stock?
As of the 2024-03-27, the market capitalization of Kura Oncology is 1.555B.

When is the next earnings date for Kura Oncology?
The upcoming earnings date for Kura Oncology is May 08, 2024.
Click to get the best stock tips daily for free!

About Kura Oncology

Kura Oncology Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, includi... KURA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT